Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson′s disease

Indian Journal of Pharmacology

Volumn 45, Issue 6, 2013, Pages 547-555

  Grover, Neeta D ^a   Limaye, Ramachandra P ^a   Gokhale, Dilip V ^a   Patil, Tatyasaheb R ^a  

^a BHARATI VIDYAPEETH UNIVERSITY   (India)

Author keywords

Neuroprotection; Parkinson's Disease; Zonisamide

Indexed keywords

LEVODOPA; PLACEBO; ZONISAMIDE;

APATHY; BARRATT IMPULSIVENESS SCALE; CONSTIPATION; DOPAMINE RELEASE; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; EX VIVO STUDY; FAMILY HISTORY; HUMAN; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MICRODIALYSIS; NEUROPROTECTION; NEUROTOXICITY; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SAMPLE SIZE; SIDE EFFECT; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT REDUCTION;

NEUROPROTECTION; PARKINSON'S DISEASE; ZONISAMIDE;

ANTIPARKINSON AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DOPAMINE; EVIDENCE-BASED MEDICINE; HUMANS; ISOXAZOLES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84890061949     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.121266     Document Type: Review

References (104)

1. Fahn S, Przedbroski S. Parkinson's Disease. In: Rowland LP, Pedley TA, editors. Chapter in Merritt's Neurology. 12th ed. Wolters Kluwer-Lippincott Williams and Wilkins,Philadelphia; 2010. p. 751-69.
2. Standaert DG, Roberson ED. Treatment of central nervous system degenerative disorders. In: Brunton LL, editor. Chapter in Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. McGraw Hill, NewYork; 2011. p. 609-28.
3. Schapira AV. Treatment options in modern management of PD. Arch Neurol 2007; 64: 1083-8.
4. Weintraub D, Comella CL, Horn S. Parkinson's Disease- Part 2: Treatment of motor symptoms. Am J Manag Care 2008; 14: S49-58.
5. Rogawski MA, Porter RJ. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990; 42: 223-86.
6. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12: 21-7.
7. Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003; 116: 1-6.
8. Okada M, Kawata Y, Mizuno K, Kondo T, Otani K, Fukushima Y. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124: 1277-85.
9. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995; 22: 193-205.
10. Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999; 34: 187-97.
11. Kawata Y, Okada M, Murakami T, Mizuno K, Wada K, Kondo T, et al. effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus. Epilepsy Res 1999; 35: 173-82.
12. Pharmaceuticals and Medical Devices Agency Japan. Tablet Trerief 25 mg, approved by PMDA, Japan on Jan 21st 2009. Accessed from the official website of PMDA. Available from: http://www.pmda.go.jp/english/service/pdf/list/ NewdrugsFY2008.pdf [Last accessed in 2012 Jun].
13. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The unified Parkinson's disease rating scale: status and recommendations. Mov Disord 2003; 18: 738-750.
14. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: Status and Recommendations. Mov Disord 2004; 19: 1020-8.
15. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001; 41: 397-9.
16. Nakanishi I, Kohomoto J, Miwa H, Kondo T. Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No To Shinkei 2003; 55: 685-9.
17. Murata M, Hasegawa K, Kanazawa I; The Japan Zonisamide Study Group. Randomized, double-blind study of zonisamide with placebo in advanced Parkinson's disease. Mov Disord 2004; 19: P555.
18. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson's disease: A randomized, double- blind study. Neurology 2007; 68: 45-50.
19. Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010; 257: 1682-5.
20. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008; 64: S93-100.
21. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson's disease: A cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-95.
22. Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, Patton JH. Fifty years of the Barratt Impulsiveness Scale: An update and review. Pers Individ Dif 2009; 47: 385-95.
23. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The movement disorder society evidence based medicine review update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26: 2-41.
24. Olanow WC. The Pathogenesis of Cell Death in Parkinson's Disease-2007. Mov Disord 2007; 22: S335-42.
25. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012; 2012: 845618.
26. Hisahara S, Shimohama S. Toxin-induced and genetic models of Parkinson's disease. Parkinsons Dis 2010; 2011: 951709.
27. Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson's disease. Parkinsons Dis 2010; 2011: 658083.
28. Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol 2007; 5: 19-33.
29. Hasegawa T. Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson's disease. Int J Mol Sci 2010; 11: 1082-9.
30. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, et al. An in vitro model of Parkinson's disease: Linking mitochondrial Iimpairment to altered α synuclein metabolism and oxidative damage. J Neurosci 2002; 22: 7006-15.
31. Margolis EB, Coker AR, Driscoll JR, Lemiatre AI, Fields HL. Reliability in the identification of midbrain dopamine neurons. PLoS One 2010; 5: e15222.
32. Asanuma M, Miyazaki I, Diaz-Corrales F, Ogawa N. Quinone formation as dopaminergic neuron -specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin- induced Parkinsonism. Acta Med Okayama 2004; 58: 221-33.
33. Schapira AV, Gegg M. Mitochondrial contribution to Parkinson's disease. Parkinsons Dis 2011; 2011: 1-7.
34. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K, Ogawa N, Murata M. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res 2008; 60: 106-13.
35. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M, et al. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol 2010; 67: 239-49.
36. Choudhury ME, Moritoyo T, Kubo M, Kyaw WT, Yabe H, Nishikawa N, et al. Zonosamide induced long lasting recovery of dopaminergic neurons form MPTPtoxicity. Brain Res 2011; 1384: 170-8.
37. Costa C, Tozzi A, Luchetti E, Siliquini S, Belcastro V, Tantucci M, et al. Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 2010; 221: 217-24.
38. Kawajiri S, Machida Y, Saiki S, Sato S, Hattori N. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett 2010; 481: 88-91.
39. Choudhury ME, Sugimoto K, Kubo M, Iwaki H, Tsujii T, Kyaw WT, et al. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors. Eur J Pharmacol 2012; 689: 72-80.
40. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopaminergic terminal loss in early Parkinson's disease. Ann Neurol 2005; 57: 168-75.
41. Halliday GM, Stevens CH. Glia: Initiators and progressors of pathology in Parkinson's disease. Mov Disord 2011; 26: 6-17.
42. Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H, Kato H, et al. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP(1-methyl- 4-phenyl-1,2,3,6-terahydropyridine) neurotoxicity in mice. Metab Brain Dis 2010; 25: 305-13.
43. Yano R, Yokoyama H, Kuroiwa H, Kato H, Araki T. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP- induced neurotoxicity in mice. J Mol Neurosci 2009; 39: 211-9.
44. Gluck MR, Santana LA, Granson H, Yahr Md. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J Neural Transm 2004; 111: 713-24.
45. Kubo M, Nishikawa N, Yabe H, Nagai M, Moritoyo H, Moritoyo T, et al. Zonisamide increased metabolism of dopamine neurons in MPTP-treated C57BL/6 and common marmosets. Mov Disord 2008; 23: S311.
46. Yabe H, Choudhury ME, Kubo M, Nishikawa N, Nagai M, Nomoto M. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J Pharmacol Sci 2009; 110: 64-8.
47. Yamamura S, Ohoyama K, Nagase H, Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 2009; 57: 322-31.
48. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S. Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 2001; 134: 507-20.
49. Sonsalla PK, Wong LY, Winnik B, Buckley B. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevance. Exp Neurol 2010; 221: 329-34.
50. Binda C, Aldeco M, Mattevi A, Edmondson DE. Interactions of monoamine oxidases with the antiepileptic drug zonisamide: Specificity of inhibition and structure of the human monoamine oxidase B complex. J Med Chem 2011; 54: 909-12.
51. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord 2010; 25 Suppl 1: S63-70.
52. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 2011; 198: 221-31.
53. Phase II safety and tolerability of isradipine (a potential neuroprotective agent) in patients with Parkinson's disease-Stage II. Clinical Trials Identifier NCT00753636. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00753636?term=isradipineandrank=1 [Last accessed on 2012 Aug 06].
54. Striessnig J, Koschak A, Sinnegger-Brauns MJ, Hetzenauer A, Nguyen NK, Busquet P, et al. Role of voltage gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans 2006; 34: 903-9.
55. Omura T, Asari M, Yamamoto J, Kamiyama N, Oka K, Hoshina C, et al. HRD1 levels increased by zonisamide prevented cell death and caspase-3 activation caused by endoplasmic reticulum stress in SH-SY5Y cells. J Mol Neurosci 2012; 46: 527-35.
56. Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003; 116: 1-6.
57. Okada M, Kawata Y, Mizuno K, Kondo T, Otani K, Fukushima Y. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124: 1277-85.
58. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995; 22: 193-205.
59. Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999; 34: 187-97.
60. Kawata Y, Okada M, Murakami T, Mizuno K, Wada K, Kondo T, et al. effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus. Epilepsy Res 1999; 35: 173-82.
61. Pharmaceuticals and Medical Devices Agency Japan. Tablet Trerief 25 mg, approved by PMDA, Japan on Jan 21st 2009. Accessed from the official website of PMDA. Available from: http://www.pmda.go.jp/english/service/pdf/list/ NewdrugsFY2008.pdf [Last accessed in 2012 Jun].
62. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The unified Parkinson's disease rating scale: status and recommendations. Mov Disord 2003; 18: 738-750.
63. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: Status and Recommendations. Mov Disord 2004; 19: 1020-8.
64. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001; 41: 397-9.
65. Nakanishi I, Kohomoto J, Miwa H, Kondo T. Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No To Shinkei 2003; 55: 685-9.
66. Murata M, Hasegawa K, Kanazawa I; The Japan Zonisamide Study Group. Randomized, double-blind study of zonisamide with placebo in advanced Parkinson's disease. Mov Disord 2004; 19: P555.
67. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson's disease: A randomized, double- blind study. Neurology 2007; 68: 45-50.
68. Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010; 257: 1682-5.
69. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008; 64: S93-100.
70. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson's disease: A cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-95.
71. Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, Patton JH. Fifty years of the Barratt Impulsiveness Scale: An update and review. Pers Individ Dif 2009; 47: 385-95.
72. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The movement disorder society evidence based medicine review update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26: 2-41.
73. Olanow WC. The Pathogenesis of Cell Death in Parkinson's Disease-2007. Mov Disord 2007; 22: S335-42.
74. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012; 2012: 845618.
75. Hisahara S, Shimohama S. Toxin-induced and genetic models of Parkinson's disease. Parkinsons Dis 2010; 2011: 951709.
76. Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson's disease. Parkinsons Dis 2010; 2011: 658083.
77. Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol 2007; 5: 19-33.
78. Hasegawa T. Tyrosinase-expressing neuronal cell line as in vitro model of Parkinson's disease. Int J Mol Sci 2010; 11: 1082-9.
79. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, et al. An in vitro model of Parkinson's disease: Linking mitochondrial Iimpairment to altered α synuclein metabolism and oxidative damage. J Neurosci 2002; 22: 7006-15.
80. Margolis EB, Coker AR, Driscoll JR, Lemiatre AI, Fields HL. Reliability in the identification of midbrain dopamine neurons. PLoS One 2010; 5: e15222.
81. Asanuma M, Miyazaki I, Diaz-Corrales F, Ogawa N. Quinone formation as dopaminergic neuron -specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin- induced Parkinsonism. Acta Med Okayama 2004; 58: 221-33.
82. Schapira AV, Gegg M. Mitochondrial contribution to Parkinson's disease. Parkinsons Dis 2011; 2011: 1-7.
83. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K, Ogawa N, Murata M. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res 2008; 60: 106-13.
84. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M, et al. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol 2010; 67: 239-49.
85. Choudhury ME, Moritoyo T, Kubo M, Kyaw WT, Yabe H, Nishikawa N, et al. Zonosamide induced long lasting recovery of dopaminergic neurons form MPTPtoxicity. Brain Res 2011; 1384: 170-8.
86. Costa C, Tozzi A, Luchetti E, Siliquini S, Belcastro V, Tantucci M, et al. Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 2010; 221: 217-24.
87. Kawajiri S, Machida Y, Saiki S, Sato S, Hattori N. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett 2010; 481: 88-91.
88. Choudhury ME, Sugimoto K, Kubo M, Iwaki H, Tsujii T, Kyaw WT, et al. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors. Eur J Pharmacol 2012; 689: 72-80.
89. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopaminergic terminal loss in early Parkinson's disease. Ann Neurol 2005; 57: 168-75.
90. Halliday GM, Stevens CH. Glia: Initiators and progressors of pathology in Parkinson's disease. Mov Disord 2011; 26: 6-17.
91. Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H, Kato H, et al. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP(1-methyl- 4-phenyl-1,2,3,6-terahydropyridine) neurotoxicity in mice. Metab Brain Dis 2010; 25: 305-13.
92. Yano R, Yokoyama H, Kuroiwa H, Kato H, Araki T. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP- induced neurotoxicity in mice. J Mol Neurosci 2009; 39: 211-9.
93. Gluck MR, Santana LA, Granson H, Yahr Md. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J Neural Transm 2004; 111: 713-24.
94. Kubo M, Nishikawa N, Yabe H, Nagai M, Moritoyo H, Moritoyo T, et al. Zonisamide increased metabolism of dopamine neurons in MPTP-treated C57BL/6 and common marmosets. Mov Disord 2008; 23: S311.
95. Yabe H, Choudhury ME, Kubo M, Nishikawa N, Nagai M, Nomoto M. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J Pharmacol Sci 2009; 110: 64-8.
96. Yamamura S, Ohoyama K, Nagase H, Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 2009; 57: 322-31.
97. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S. Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 2001; 134: 507-20.
98. Sonsalla PK, Wong LY, Winnik B, Buckley B. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevance. Exp Neurol 2010; 221: 329-34.
99. Binda C, Aldeco M, Mattevi A, Edmondson DE. Interactions of monoamine oxidases with the antiepileptic drug zonisamide: Specificity of inhibition and structure of the human monoamine oxidase B complex. J Med Chem 2011; 54: 909-12.
100. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord 2010; 25 Suppl 1: S63-70.
101. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 2011; 198: 221-31.
102. Phase II safety and tolerability of isradipine (a potential neuroprotective agent) in patients with Parkinson's disease-Stage II. Clinical Trials Identifier NCT00753636. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00753636?term=isradipineandrank=1 [Last accessed on 2012 Aug 06].
103. Striessnig J, Koschak A, Sinnegger-Brauns MJ, Hetzenauer A, Nguyen NK, Busquet P, et al. Role of voltage gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans 2006; 34: 903-9.
104. Omura T, Asari M, Yamamoto J, Kamiyama N, Oka K, Hoshina C, et al. HRD1 levels increased by zonisamide prevented cell death and caspase-3 activation caused by endoplasmic reticulum stress in SH-SY5Y cells. J Mol Neurosci 2012; 46: 527-35.